Vancomycin Mylan
Summary of product characteristics
1 NAME OF THE MEDICINAL PRODUCT
Vancomycin Mylan 500 mg, powder for concentrate for solution for infusion.
Vancomycin Mylan 1000 mg, powder for concentrate for solution for infusion.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains vancomycin hydrochloride corresponding to 500 mg vancomycin (equivalent to not less than 525 000 IU).
When reconstituted with 10ml of water for injections, the resulting concentrate for solution for infusion contains 50mg/ml vancomycin.
Each vial contains vancomycin hydrochloride corresponding to 1000 mg vancomycin (equivalent to not less than 1 050 000 IU.
When reconstituted with 20ml of water for injections, the resulting concentrate for solution for infusion contains 50mg/ml vancomycin.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Powder for concentrate for solution for infusion.
White or off white powder.
Reconstituted concentrate for solution for infusion has a pH of 2.5 – 4.5.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Severe infections, caused bygram-positive bacteria susceptible to vancomycin which cannot be treated with or failed to respond or are resistant to other antibiotics such as penicillins and cephalosporins:
-
complicated skin and soft tissue infections
-
bone and joint infections
-
community acquired pneumonia
-
hospital acquired pneumonia
-
infective endocarditis
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Where appropriate, vancomycin should be administered in combination with other antibacterial agents.
Vancomycin is active alone or in combination with aminoglycosides in endocarditis caused by Streptococcus viridans or S. bovis. Endocarditis caused by Enterococcus (eg Streptococcus faecalis) should be treated by a combination of vancomycin with aminoglycosides.
Vancomycin may be used for the perioperative prophylaxis against bacterial endocarditis, in patients at high risk of developing bacterial endocarditis when they undergo major surgical procedures (e.g. cardiac and vascular procedures, etc.) and are unable to receive a suitable beta-lactam antibacterial agent.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
4.2 Posology and method of administration
The dose should be individually adapted according to weight, age and the underlying type and severity of infection and the clinical response of the patient, and patient factors such asrenal function.
Where appropriate, vancomycin should be administered in combination with other antibacterial agents. Therapeutic guidelines should be adhered to.
Patients with normal renal functions, adults and children from 12 years:
The usual intravenous dose is 500 mg every 6 hours or 1 g every 12 hours. In special circumstances and for severe and life threatening infections, 15-20 mg/kg body weight every 8-12 h might be considered to achieve optimal trough concentrations (see section 5.1).
For bacterial endocarditis, the generally accepted regimen is 1000 mg vancomycin intravenously every 12 hours for 4 weeks either alone or in combination with other antibiotics.
Enterococcal endocarditis is treated for 6 weeks with vancomycin in combination with an aminoglycoside. Official guidance should be consulted.
Peri-operative
prophylaxis against bacterial endocarditis:
Adults receive 1000 mg vancomycin intravenously prior to
surgery (prior to induction of anaesthesia) and depending on time
and type of surgery, the dose of 1000 mg of vancomycin i.v. 12
hours postoperatively can be given.
Elderly patients:
The natural decrease of the glomerular filtration rate with higher age can result in an increased vancomycin serum concentration if dosage is not adapted (see table for dosage in case of impaired renal functions).
Paediatric population
Children (1 month to 12 years):
The usual intravenous daily dose is 40 mg/kg body weight, mostly in 4 single doses, that is 10 mg/kg body weight every 6 hours. The dose may be increased to 60 mg/kg bodyweight per day (see section 5.1).
Infants up to 1 month:
For young infants and new-borns the doses can be lower. The recommendation is an initial dose of 15 mg/kg body weight and maintenance doses of 10 mg/kg body weight every 12 hours in the first life week and then every 8 hours until the age of one month. The blood concentrations of vancomycin should be monitored.
Patients with impaired renal functions
In patients with impaired renal function the dosage has to be adapted to the excretion rate. In that case the evaluation of the vancomycin serum level may be helpful, especially in severely ill patients with changing renal function.
The following dosage table can serve as guidance for patients with impaired renal function. The initial dose should be not less than 15 mg/kg body weight.
|
Creatinine clearance [ml/min] |
Vancomycin dosage [mg/24 hours] |
|
> 100 |
2000-1500 |
|
100-70 |
1500-1000 |
|
70-30 |
1000-500 |
|
20 |
300 |
|
10 |
150 |
Patients with anuria
The initial dose is 15 mg/kg to achieve therapeutic levels. The maintenance dose is about 1.9 mg/kg/24 hours. In order to facilitate the procedure, adult patients with strongly impaired renal function may obtain a maintenance dose of 250 - 1000 mg at intervals of several days instead of a daily dose.
Dosage in case of haemodialysis
For patients with anuria, and also receiving a regular hemodialysis, the following dosage is possible: saturating dose 1000 mg, maintenance dose 1000 mg every 7-10 days.
If polysulfon membranes are used for hemodialysis („high flux dialysis“), the half time of vancomycin is shortened. For patients with regular hemodialysis a higher maintenance dose may be necessary.
Patients with hepatic impairment
There is no evidence that the dose has to be reduced in patients with hepatic insufficiency.
Monitoring of vancomycin serum concentrations:
The serum concentration of vancomycin should be monitored at the second day of treatment immediately prior to the next dose, and one hour post infusion. Therapeutic trough (minimum) vancomycin blood levels should normally be ≥10 mg/l.Depending onthe site of infection and susceptibilityof the pathogen trough values of 15-20 mg/l may be neededto achieve efficacy (see sections 4.4and 5.1).
The concentrations should normally be monitored twice or three times per week.
Method of administration
Parenterally vancomycin shall only be administered as slow intravenous infusion (not more than 10 mg/min, as well single doses lower than 600 mg over at least 60 min) which is sufficiently diluted (at least 100 ml per 500 mg or at least 200 ml per 1000 mg).
Patients whose fluid intake must be limited can also receive a solution of 500 mg/50 ml or 1000 mg/100 ml. With these higher concentrations the risk for infusion related side effects can be increased.
For information about the preparation of the solution, please see section 6.6.
4.3 Contraindications
Hypersensitivity to vancomycin or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
Hypersensitivity reactions
In case of severe acute hypersensitivity reactions (e.g. anaphylaxis), the treatment with vancomycin has to be discontinued immediately and the usual appropriate emergency measures have to be started.
In patients receiving vancomycin over a longer-term period or concurrently with other medications which may cause neutropenia or agranulocytosis, the leukocyte count should be monitored at regular intervals. All patients receiving vancomycin should have periodic haematologic studies, urine analysis, liver and renal function tests.
Ototoxicity
Ototoxicity, which may be transitory or permanent (see section 4.8) has been reported in patients with prior deafness, who have received excessive intravenous doses, or who receive concomitant treatment with another ototoxic active substance such as an aminoglycoside. Deafness may be preceded by tinnitus. Experience with other antibiotics suggests that deafness may be progressive despite cessation of treatment. To reduce the risk of ototoxicity, blood levels should be determined periodically and periodic testing of auditory function is recommended.
The elderly are particularly susceptible to auditory damage.Monitoring of vestibular and auditory function in the elderly should be carried out during and after treatment. Concurrent or sequential use of other ototoxic substances should be avoided.
Infusion related reactions
Rapid bolus administration (i.e. over several minutes) may be associated with exaggerated hypotension (including shock and, rarely, cardiac arrest), histamine like responses and maculopapular or erythematous rash (“red man’s syndrome” or “red neck syndrome”).
Vancomycin should be infused slowly in a dilute solution (2.5 to 5.0 g/l) at a rate no greater than 10mg/min and over a period not less than 60 minutes to avoid rapid infusion-related reactions. Stopping the infusion usually results in a prompt cessation of these reactions.
Pain and thrombophlebitis may occur in many patients receiving vancomycin and are occasionally severe. The frequency and severity of thrombophlebitis can be minimized by administering the medicinal product slowly as a dilute solution (see section 6.6) and by changing the sites of infusion regularly. The frequency of infusion-related reactions (hypotension, flushing, erythema, urticaria and pruritus) increases with the concomitant administration of anaesthetic agents(see section 4.5 for more information).This may be reduced by administering the vancomycin by infusion over 60 minutes, before anaesthetic induction.
Severe bullous reactions
Stevens-Johnson syndrome (SJS) have been reported with the use of vancomycin. If symptoms or signs of SJS (e.g. progressive skin rash often with blisters or mucosal lesions) are present, vancomycin treatment should be discontinued immediately
Spectrum of antibacterial activity
Vancomycin has a limited spectrum of antibacterial activity (Gram positive). It is not suitable for use as a single agent for the treatment of some types of infections unless the pathogen is already documented and known to be susceptible or there is a high suspicion that the most likely pathogen(s) would be suitable for treatment with vancomycin.
The rational use of vancomycin should take into account the bacterial spectrum of activity, the safety profile and the suitability of standard antibacterial therapy to treat the individual patient.
Administration site related reactions
Vancomycin must be administered only by intravenous use, owing to the risk of necrosis. The risk of venous irritation is minimized by giving vancomycin in the form of a dilute infusion and by changing the injection site.Vancomycin is very irritating to tissue and causes injection site necrosis if injected intramuscularly.
The administration of vancomycin by intraperitoneal injection during continuous ambulatory peritoneal dialysis has been associated with a syndrome of chemical peritonitis.
Vancomycin should be used with caution in patients with allergic reactions to teicoplanin, since crosshypersensitivity, including fatal anaphylactic shock, reactions have been reported.
Nephrotoxicity
Vancomycin should be used with care in patients with renal insufficiency, including anuria, as the possibility of developing toxic effects is much higher in the presence of prolonged high blood concentrations. The dose should be reduced according to the degree of renal impairment. The risk of toxicity is increased by high blood concentrations or prolonged therapy. Blood levels should be monitored and renal function tests should be performed regularly.
Regular monitoring of the blood levels of vancomycin is indicated in high dose therapy and longer-term use, particularly in patients with renal dysfunction or impaired faculty of hearing as well as in concurrent administration of nephrotoxic or ototoxic substances, respectively (see section 4.2).
Paediatric population
Vancomycin should be used with particular care in premature infants and children, because of their renal immaturity and the possible increase in the serum concentration of vancomycin (see section 4.2). The blood concentrations of vancomycin should therefore be monitored carefully. Concomitant administration of vancomycin and anaesthetic agents has been associated with erythema and histamine-like flushing in children (see section 4.5).
Drug interactionswith anaesthetic agents
Anaesthetic induced myocardial depression may be enhanced by vancomycin. During anaesthesia, doses must be well diluted and administered slowly with close cardiac monitoring. Position changes should be delayed until the infusion is completed to allow for postural adjustment. (see section 4.5).
Pseudomembranous enterocolitis
In case of severe persistent diarrhoea the possibility of pseudomembranous enterocolitis that might be life-threatening has to be taken into account (see section 4.8). Anti-diarrhoeic medicinal products must not be given.
Superinfection Prolonged use of vancomycin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.
4.5 Interaction with other medicinal products and other forms of interaction
Other potentially nephro- or ototoxic medicinal products
A concomitant or sequential administrationof vancomycin and other potentially oto- or nephrotoxic medicinal products can increase the oto- or nephrotoxicity. Nephrotoxic medicinal products can be iodine contrast agents, aminoglycosides, organoplatines, methotrexate at high doses, and some antiviral drugs such as pentamidine, foscarnet, aciclovir, ganciclovir, famciclovir, valaciclovir, valganciclovir,ciclosporin or tacrolimus. Ototoxic medicinal products can be aminoglycosides, organoplatines, some diuretics. Particularly in cases of concomitant aminoglycoside administration, a careful monitoring is necessary. In these cases the maximal dose of vancomycin is to be limited to 500 mg every 8 hours.
Anaestetics
It is reported that the incidence of potential side effects (like hypotension, skin erubescence, erythema, urticaria, myocardial depression and pruritus) increases when vancomycin is concomitantly administered with anesthetics. In order to avoid side effects, vancomycin should be administered at least 60 minutes before induction of the anaesthesia (see section 4.4).
Muscle relaxants
If vancomycin hydrochloride is applied during or immediately after surgery, effects of concomitantly administered muscle relaxants (e. g. succinylcholin), such as neuromuscular block, can be intensified or prolonged.
Oral anticoagulants
Concomitant administration of vancomycin with warfarin may augment its anti-coagulant effects. There have been many reports of increases in oral anti-coagulant activity in patients receiving antibacterial agents, including glycopeptides. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the glycopeptides to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of vancomycin with an oral anti‑coagulant agent.
Paediatric population
Interaction studies have only been performed in adults.
4.6 Fertility, pregnancy and lactation
Pregnancy
There are no adequate data from the use of vancomycin in pregnant patients. Animal studies do not indicate direct or indirect harmfuleffects
with respect to reproductive toxicity during development (see section 5.3).
Vancomycin crosses the placenta and a potential risk of embryonal and neonatal ototoxicity and nephrotoxicity cannot be excluded. Vancomycin should be given in pregnancy only if clearly needed and after a careful risk/benefit evaluation.
Lactation
Vancomycin is excreted in human breast milk. Caution should be used when vancomycin is given to breast-feeding mothers because of potential adverse reactions in the infant (disturbances in the intestinal flora with diarrhoea, colonisation with yeast-like fungi and possibly sensibilisation). Considering the importance of this medical product for a nursing mother, a decision must be made whether to discontinuebreastfeeding or to discontinue/abstain from vancomycin therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Fertility
There are no data available.
4.7 Effects on ability to drive and use machines
Vancomycin Mylan has no or negligible influence on the ability to drive and use machines.
4.8 Undesirable effects
The most common side effects are phlebitis and pseudo-allergic reactions caused by a rapid intravenous infusion of vancomycin.
Table 1: Tabulated adverse reactions
|
System organ class |
Common (1/100 to <1/10) |
Uncommon (1/1,000 to <1/100) |
Rare (1/10,000 to <1/1,000) |
Very rare (<1/10,000) |
Frequency not known |
|
Blood and lymphatic system disorders |
|
|
Agranulocytosis, Neutropenia, Thrombocytopenia, Eosinophilia, Leucopenia, Anemia, Pancytopenia, Aplastic anemia1 |
|
|
|
Immune system disorders |
|
|
Anaphylactoid reactions, Hypersensitivity reactions |
|
DRESS |
|
Ear and labyrinth disorders |
|
Ototoxicity |
Tinnitus, Dizziness |
|
|
|
Cardiac disorders |
|
|
|
Cardiac arrest |
|
|
Vascular disorders |
Hypotension, Thrombophlebitis |
|
|
Vasculitis |
|
|
Respiratory, thoracic and mediastinal disorders |
Dyspnoe, Stridor |
|
|
|
|
|
Gastrointestinal disorders |
|
|
Nausea, Vomiting |
Pseudomembranous enterocolitis |
|
|
Skin and subcutaneous tissue disorders |
Exanthema, mucosal inflammation, Pruritus, Urticaria |
|
Linear IgA bullous dermatosis |
Exfoliative dermatitis, Stevens-Johnson-Syndrome, Lyell-syndrome, Acute generalised exanthematous pustulosis |
|
|
Renal and urinary disorders |
Renal insufficiency |
|
Interstitial nephritis, Acute renal failure |
|
Acute tubular necrosis |
|
General disorders and administration site conditions |
Phlebitis, Red man syndrome, Pain, Spasm |
|
Drug fever, Chills |
|
|
Description of selected adverse reactions
Furthermore, administration of vancomycin may decrease the response to platelet transfusions following allogeneic hematopoietic stem cell transplantation.
Reporting of suspected adversereactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V*
4.9 Overdose
Overdose symptoms include ototoxicity, red man syndrome and renal insufficiency with elevated serum creatinine or serum urea concentrations.
Measures in case of overdose
-
A specific antidote is not known.
-
Symptomatic treatment while maintaining renal function is required.
Vancomycin is poorly removed from the blood by haemodialysis or peritoneal dialysis. Haemofiltration or haemoperfusion with polysulfone resins have been used to reduce serum concentrations of vancomycin.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antibacterials for systemic use: Glycopeptide antibacterials. ATC code J01XA01.
Mechanismof action:
Vancomycin is a tricyclic glycopeptide antibiotic that inhibits the syntesis of the cell wall in sensitive bacteria by binding with high affinity to the D-alanyl-D-alanine terminus of cell wall precursor units. The drug is bactericidal for dividing microorganisms.
Pharmacokinetic/ Pharmacodynamicrelationship:
Vancomycin displays concentration-independent activity with the area under the concentration curve (AUC) divided by the the minimum inhibitory concentration (MIC) of the target organism as the primary predictive parameter for efficacy. On basis of in vitro, animal and limited human data, an AUC/MIC ratio of 400 has been established as a PK/PD target to achieve clinical effectiveness with vancomycin. To achieve this target when MICs are > 0.5 mg/l, dosing in the upper range and high trough serum concentrations (15-20 mg/l) are required (see section 4.2).
Mechanism of resistance:
Acquired resistance to glycopeptides is based on acquisition of various van gene complexes and alteration of the D-alanyl-D-alanine target to D-alanyl-D-lactate or D-alanyl-D-serine which bind vancomycin poorly, because a critical site for hydrogen bonding is missing. This form of resistance is especially seen in Enterococcus faecium.
The reduced susceptibility or resistance to vancomycin in Staphylococcusis not well understood. Several genetic elements and multiple mutations are required.
Cross-resistance with teicoplanin has been reported.
Susceptibility:
Vancomycin is active against gram-positive bacteria. Gram-negative bacteria are resistant.
The MIC breakpoints separating susceptible from resistant organisms are as follows:
EUCAST (European Committee on Antimicrobial Susceptibility Testing) recommendations
|
|
Susceptible |
Resistant |
|
Staphylococcus spp. |
2 mg/l |
> 2 mg/l |
|
Enterococcus spp.1 |
4 mg/l |
> 4 mg/l |
|
Streptococcus spp |
2 mg/l |
> 2 mg/l |
|
Streptococcus pneumoniae |
2 mg/l |
> 2 mg/l |
|
Gram-positive anaerobes |
£ 2 mg/l |
> 2 mg/l |
|
Non species related2 |
2 mg/l |
> 4 mg/l |
1 The S/I breakpoint for vancomycin has been raised to 4 mg/l to avoid dividing the wild type MIC distributions of some species.
2 Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and not for those species where susceptibility testing is not recommended.
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.
|
Commonly susceptible species |
|
Gram positive |
|
Enterococcus faecalis. |
|
Staphylococcus aureus |
|
Staphylococcus coagulase negative |
|
Streptococcus spp. |
|
Streptococcus pneumoniae |
|
Bacillus spp., Enterococcus spp., Listeria spp., Rhodococcus equi, |
|
Anaerobic species Clostridium spp. except Clostridium innocuum Eubacterium spp. Peptostreptococcus spp. Propionibacterium acnes |
|
Species for which acquired resistance may be a problem |
|
Enterococcus faecium |
|
Inherently resistant |
|
Gram negative bacteria |
|
Chlamydia spp. Cocci and bacilli Gram positive aerobic species Actinomyces spp., Erysipelothrix rhusiopathiae, Heterofermentative Lactobacillus, Leuconostoc spp., Nocardia asteroides, Pediococcus spp.
Anaerobic species |
|
Clostridium innocuum Mycobacteria |
|
Mycoplasma spp. |
|
Others Chlamydia spp Rickettsia spp. Treponema spp. |
5.2 Pharmacokinetic properties
Absorption
The mean plasma levels after intravenous infusion of 1 g vancomycin over 60 minutes were approximately 63 mg/l at the end of infusion, approximately 23 mg/l after 2 hours , and approximately 8 mg/l after 11 hours.
If vancomycin is administered during a peritoneal dialysis intraperitoneally, approximately 60% reach the systemic cycle during the first 6 hours. After intraperitoneal administration of 30 mg/kg serum levels of approximately 10 mg/l are reached.
Vancomycin is normally not absorbed through the gastrointestinal track. However, inflammation of the gut wall appears to increase Vancomycin bioavailability, resulting in some systemic absorption. As oral vancomycin has a local effect in the gastrointestinal tract, it is well suitable for treatment of colitis.
Distribution
After intravenous administration vancomycin is distributed in nearly all tissues. In pleura, pericard, ascites and synovia liquid as well as in heart muscle and in heart valve concentrations similar to those in blood plasma are achieved. The apparent distribution volume in the steady state is named to be 0.43 (up to 0.9) l/kg. In case of non-inflammatory meninges only small quantities of vancomycin pass into the cerebrospinal fluid.
Vancomycin is bound to plasma proteins to 55%.
Elimination
It is metabolised only to a small extent. After parenteral administration it is excreted renally via glomerular filtration, nearly completely as the microbiologcally active substance (approximately 70-80% within 24 h). Biliar excretion has low relevance (less than 5% of a dose). The serum half life in adult patients with normal renal functions is about 4-6 hours, in children 2.2-3 hours. Impaired renal function can prolong the elimination (up to 7.5 days). The clearance of vancomycin from the plasma correlates approximately with the glomerular filtration rate. The total systemic and renal clearance of vancomycin can be reduced in elderly patients.
5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and repeated dose toxicity. Limited data on mutagenic effects are available, they show no indication of any hazard. Long-term studies in animals regarding a carcinogenic potential are not available. In teratogenicity studies, where rats and rabbits received doses approximately corresponding to the human dose based on body surface (mg/m2), no direct or indirect teratogenic effects were observed. Animal studies of the use during the perinatal/postnatal period and regarding effects on fertility are not available.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Sodium hydroxide (for pH adjustment),
Hydrochloric acid (for pH adjustment)
6.2 Incompatibilities
Vancomycin Mylan has a low pH value. This may lead to chemical or physical instability if mixed with other substances. Therefore, each parenteral solution should be checked visually for precipitations and discolouration prior to use.
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
Combination therapy
In case of combination therapy of vancomycin with other antibiotics/chemotherapeutics, the preparations should be administered separately.
Mixtures of solutions of vancomycin and beta-lactam antibiotics have been shown to be physically incompatible. The likelihood of precipitation increases with higher concentrations of vancomycin. It is recommended to adequately flush the intravenous lines between administration of these antibiotics. It is also recommended to dilute solutions of vancomycin to 5 mg/mL or less.
Vancomycin Mylan is not licensed for administration as intravitreal injection. Precipitation has been observed following intravitreal injection of vancomycin and ceftazidim using separate syringes and needles for the treatment of endophthalmitis. The precipitate in the vitreous body dissolved completely but slowly over a period of 2 months, during which visual acuity also improved.
6.3 Shelf life
Powder:2 years
Reconstituted concentrate for solution for infusion: Chemical and physical in-use stability has been demonstrated for 24 hours stored at 2-8°C.
Prepared solution for infusion: Chemical and physical in-use stability has been demonstrated for 12 hours stored at 25°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, the total in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
6.4 Special precautions for storage
Powder:Do not store above 25°C.
For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.
6.5 Nature and contents of container
Colourless type I glass vial with 20 mm rubber stopper and flip off aluminium seal.
Pack size of 1 vial containing 500 mg or 1000 mg powder of active substance.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling
The powder must be reconstituted and the resulting concentrate must then be diluted further prior to use.
Preparation of the infusion concentrate
Dissolve the contents of a 500 mg vancomycin vial in 10 ml of sterile water.
Dissolve the contents of a 1000 mg vancomycin vial in 20 ml of sterile water.
One ml of reconstituted solution contains 50 mg of vancomycin.
pH=2.5 – 4.5.
To prevent precipitation due to the low pH of vancomycin hydrochloride in solution, all intravenous cannulae and catheters should be flushed with saline.
Appearance of the infusion concentrate
Clear, colorless solution free from particles.
For storage conditions of the reconstituted medicinal product, see sections 6.3
Preparation of the solution for infusion
Vancomycin Mylan may be diluted with sterile water, 9 mg/ml sodium chloride or 50 mg/ml glucose.
Vial containing 500 mg vancomycin:
To obtain a 5 mg/ml solution for infusion dilute10 ml of the infusion concentrate with 90 ml of 9 mg/ml sodium chloride or 50 mg/ml glucose, and administer as intravenous infusion.
Vial containing 1000 mg vancomycin:
To obtain a 5 mg/ml solution for infusion dilute20 ml of the infusion concentrate with 180 ml of 9 mg/ml sodium chloride or 50 mg/ml glucose, and administer as intravenous infusion.
Appearance of solution for infusion
The solution is to be inspected visually for particulate matter and discoloration prior to administration. The solution should only be used if the solution is clear and free from particles.
The concentration of vancomycin in Solution for infusion should not exceed 5 mg/ml.
The desired dose should be administered slowly by intravenous infusion at a rate of no more than 10 mg/minute, for at least 60 minutes or even longer.
For storage conditions of the diluted medicinal product, see sections 6.3
Example:A dose of 20 mg/kg body weight for a child (10 kg) requires 200 mg vancomycin, which is equivalent to 40 ml of the solution for infusion.
The rate of infusion should under no circumstances exceed 10 mg/min. Handling instructions are included in the package.
Disposal
Vials are for single use only. Unused product must be discarded.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
Mylan Hospital AS
Sørkedalsveien 10B
NO-0369 OSLO
Norway
8 MARKETING AUTHORISATION NUMBER(S)
<To be completed nationally>
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
12 November 2012
10 DATE OF REVISION OF THE TEXT
17 September 2015